Return to previous page|
Northern Hemisphere 2010/2011 and Southern Hemisphere 20101
Candidate influenza vaccine viruses
NIBSC code
H1N12
A/California/7/2009 wild type virus
10/122
NYMC X-179A reassortant derived from A/California/7/2009
09/216
NYMC X-181 reassortant derived from A/California/7/2009
09/314
IVR-153 reassortant derived from A/California/7/2009
09/236
NIBRG-121 reassortant derived from A/California/7/2009
09/122
NIBRG-121xp reassortant derived from A/California/7/2009
09/268
NIBRG-122 reassortant derived from A/England/195/2009
09/130
H3N2
A/Perth/16/2009 wild type virus
09/208
NIB-64 reassortant derived from A/Perth/16/2009
09/280
NYMC X-183 reassortant derived from A/Wisconsin/15/2009
09/248
09/274
09/290
09/298
09/304
B
B/Brisbane/60/2008
09/168
B/Brisbane/33/2008
08/280
NYMC BX-31 reassortant derived from B/Brisbane/60/2008
08/360
NIB-58 reassortant derived from B/Brisbane/60/2008
08/364
NYMC BX-35 reassortant derived from B/Brisbane/60/2008
09/318
1 WHO recommendations for influenza virus vaccines for use in the 2010/2011 northern hemisphere influenza season.
2 For further information on the candidate pandemic H1N1 vaccine viruses.
Reagents for influenza vaccine standardisation
H1N1
A/California/7/2009 (NYMC X-179A) egg derived antigen
09/146
A/California/7/2009 (NYMC X-179A) cell derived antigen
09/174
A/California/7/2009 (NIBRG-121xp) egg derived antigen
09/196
09/294
A/California/7/2009 antiserum
10/118
A/Perth/16/2009 like antigen A/Wisconsin/15/2009 (NYMC X-183)
09/310
A/Perth/16/2009 like antigen A/Victoria/210/2009 (NYMC X-187)
10/102
A/Perth/16/2009 like antiserum
10/148
B/Brisbane/60/2008 antigen
08/352
B/Brisbane/60/2008 like antigen (NYMC BX-35)
10/106
B/Brisbane/60/2008 like antiserum
10/146
Neuraminidase reagents
N1
antiserum prepared from A/New Caledonia/20/99
04/230
N2
antiserum prepared from A/Wyoming/3/2003
04/258
NA antiserum prepared from B/Jiangsu/10/2003
04/228
NA antiserum prepared from B/Malaysia/2506/2004
05/252
NA antiserum prepared for B/Florida/4/2006
09/316
Northern Hemisphere 2009/2010 3
A/Brisbane/59/2007
09/276
IVR-148 reassortant derived from A/Brisbane/59/2007
08/300
A/Brisbane/10/2007 wild type virus
07/250
A/Uruguay/716/2007 wild type virus-
07/354
NIB-50 reassortant derived from A/Uruguay/716/2007
07/358
IVR-149 reassortant derived from A/Uruguay/716/2007
07/362
NYMC X-175C reassortant derived from A/Uruguay/716/2007
08/304
3WHO recommended composition of influenza virus vaccines for use in the 2009/2010 northern hemisphere influenza season.
Pricing information
Viruses are free of charge (normally a maximum of two vials per recipient), but customers are expected to pay shipping and packing costs. Reagents for Single Radial Diffusion assay are subject to the usual NIBSC handling charge of £63 per vial, plus shipping and packing costs. Approved National Control Laboratories for human health are exempt from the £63 handling fee.